Market Overview

Roth Capital Upgraded Peregrine Pharma Following Internal Review of Trial

Related PPHM
Mid-Day Market Update: Trex Rises After Strong Q3 Results; Under Armour Shares Slide
Earnings Scheduled For September 11, 2017
Week 47 Breakout Forecast: Short-Term Picks To Give You An Edge (Seeking Alpha)

Roth Capital upgraded Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) following news of an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients.

The firm raised its rating from Neutral to Buy and boosted its price target from $1.25 to $2.70.

Latest Ratings for PPHM

Feb 2016Roth CapitalDowngradesBuyNeutral
Feb 2016Roth CapitalDowngradesBuyNeutral
Mar 2014McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for PPHM
View the Latest Analyst Ratings

Posted-In: News Upgrades Analyst Ratings


Related Articles (PPHM)

View Comments and Join the Discussion!

Partner Center